<p>巴克莱银行在最近向证券交易委员会的披露中表示，在第四季度将其在 Corvus Pharmaceuticals, Inc.（NASDAQ:CRVS - 免费报告）中的持股增加了 10,601,800.0%。该机构投资者在此期间购买了额外的 106,018 股后，拥有 106,019 股公司的股票。巴克莱银行在最近一个季度末持有的 Corvus Pharmaceuticals 股份占 0.16%，价值为 567,000 美元。</p>
<p>获取 <strong>Corvus Pharmaceuticals</strong> 的提醒：</p>
<p>其他几家对冲基金和机构投资者最近也对 CRVS 的持仓进行了调整。Jane Street Group LLC 在第三季度收购了价值约 265,000 美元的 Corvus Pharmaceuticals 新头寸。Virtu Financial LLC 在第三季度购买了价值约 83,000 美元的 Corvus Pharmaceuticals 新股份。摩根大通在第三季度将其在 Corvus Pharmaceuticals 的持股增加了 441.5%。摩根大通现在拥有 49,556 股公司的股票，价值为 262,000 美元，此前在上个季度又收购了 40,404 股。Avity Investment Management Inc.在第四季度将其在 Corvus Pharmaceuticals 的持股增加了 7.6%。Avity Investment Management Inc.现在拥有 29,680 股公司的股票，价值为 159,000 美元，此前在上个季度又收购了 2,100 股。最后，Masso Torrence Wealth Management Inc.在第四季度将其在 Corvus Pharmaceuticals 的持仓提高了 200.0%。Masso Torrence Wealth Management Inc.现在拥有 30,000 股公司的股票，价值为 160,000 美元，此前在上个季度又购买了 20,000 股。对冲基金和其他机构投资者持有该公司 46.64% 的股份。</p>
<h2>Corvus Pharmaceuticals 股价上涨 4.7%</h2>
<p>NASDAQ CRVS 的股票在周五开盘价为 3.35 美元。该公司的 50 日简单移动平均为 3.61 美元，200 日简单移动平均为 5.51 美元。该股票的市值为 2.2837 亿美元，市盈率为-3.60，贝塔值为 0.67。Corvus Pharmaceuticals, Inc.的 12 个月低点为 1.75 美元，12 个月高点为 10.00 美元。</p>
<p>Corvus Pharmaceuticals（NASDAQ:CRVS - 获取免费报告）最近在 5 月 5 日（星期一）发布了季度财报。该公司报告季度每股收益（EPS）为（0.13）美元，低于市场共识预期的（0.12）美元，差距为（0.01）美元。分析师预测 Corvus Pharmaceuticals, Inc.在本年度的每股收益将为-0.63 美元。</p>
<h2>华尔街分析师观点</h2>
<p>多家券商对 CRVS 发布了报告。Oppenheimer 在 3 月 26 日的研究报告中重申了 “跑赢大盘” 的评级，并将 Corvus Pharmaceuticals 的目标价设定为 15.00 美元（之前为 14.00 美元）。HC Wainwright 在 3 月 26 日的研究报告中重新发布了 “买入” 评级，并对 Corvus Pharmaceuticals 的目标价为 11.00 美元。一位投资分析师对该股票给予了卖出评级，三位分析师给予了买入评级，一位分析师给予了强烈买入评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 15.67 美元。</p>
<p><strong>阅读我们关于 Corvus Pharmaceuticals 的最新报告</strong></p>
<h2>Corvus Pharmaceuticals 公司简介</h2>
<p>（免费报告）</p>
<p>Corvus Pharmaceuticals, Inc.是一家临床阶段的生物制药公司，专注于开发和商业化免疫调节剂产品候选药物，以治疗实体癌症、T 细胞淋巴瘤、自身免疫性疾病、过敏性疾病和传染病。其主要产品候选药物是 soquelitinib（CPI-818），这是一种选择性共价抑制剂，针对白细胞介素 2 诱导的 T 细胞激酶（ITK），目前正在进行多中心的 1/1b 期临床试验，治疗外周 T 细胞淋巴瘤、实体肿瘤和特应性皮炎。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票，胜过 Corvus Pharmaceuticals</li>
<li>TSX 风险投资交易所（前称加拿大风险投资交易所）</li>
<li>IBM 的人工智能攻势：评估 IBM 重获增长的路径</li>
<li>即将到来的 IPO 股票锁定期，解读</li>
<li>罗克韦尔自动化：美国生产回流的顺风</li>
<li>复利及其在投资中的重要性</li>
<li>能源转移是被低估还是价值陷阱？</li>
</ul>
<p><strong>想看看其他对冲基金持有的 CRVS 吗？</strong> 访问 HoldingsChannel.com，获取 Corvus Pharmaceuticals, Inc.（NASDAQ:CRVS - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JWUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JWUw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Corvus Pharmaceuticals 吗？</h2>
<p>在考虑投资 Corvus Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Corvus Pharmaceuticals 并不在名单上。</p>
<p>虽然 Corvus Pharmaceuticals 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

Corvus制药

巴克莱银行

<p>巴克莱银行在第四季度显著增加了对 Corvus Pharmaceuticals, Inc.（纳斯达克代码：CRVS）的持股，增幅达到 10,601,800.0%，目前持有 106,019 股，价值为 567,000 美元。其他机构投资者也调整了他们的持仓，对该公司的对冲基金持股比例为 46.64%。Corvus Pharmaceuticals 的股价上涨了 4.7%，达到 3.35 美元，市值为 2.2837 亿美元。分析师对该公司的共识评级为 “适度买入”，平均目标价为 15.67 美元。该公司专注于开发用于各种疾病的免疫调节产品，包括实体癌症</p>

<p>Barclays PLC raised its holdings in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 10,601,800.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 106,019 shares of the company's stock after purchasing an additional 106,018 shares during the period. Barclays PLC owned 0.16% of Corvus Pharmaceuticals worth $567,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>巴克莱银行在最近向证券交易委员会的披露中表示，在第四季度将其在 Corvus Pharmaceuticals, Inc.（NASDAQ:CRVS - 免费报告）中的持股增加了 10,601,800.0%。该机构投资者在此期间购买了额外的 106,018 股后，拥有 106,019 股公司的股票。巴克莱银行在最近一个季度末持有的 Corvus Pharmaceuticals 股份占 0.16%，价值为 567,000 美元。</p>
</div><p>Get <strong>Corvus Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Corvus Pharmaceuticals</strong> 的提醒：</p>
</div><p>Several other hedge funds and other institutional investors have also recently made changes to their positions in CRVS. Jane Street Group LLC acquired a new position in Corvus Pharmaceuticals during the 3rd quarter valued at about $265,000. Virtu Financial LLC purchased a new stake in shares of Corvus Pharmaceuticals during the third quarter worth about $83,000. JPMorgan Chase &amp; Co. increased its holdings in shares of Corvus Pharmaceuticals by 441.5% during the third quarter. JPMorgan Chase &amp; Co. now owns 49,556 shares of the company's stock valued at $262,000 after acquiring an additional 40,404 shares in the last quarter. Avity Investment Management Inc. increased its holdings in shares of Corvus Pharmaceuticals by 7.6% during the fourth quarter. Avity Investment Management Inc. now owns 29,680 shares of the company's stock valued at $159,000 after acquiring an additional 2,100 shares in the last quarter. Finally, Masso Torrence Wealth Management Inc. raised its position in shares of Corvus Pharmaceuticals by 200.0% in the 4th quarter. Masso Torrence Wealth Management Inc. now owns 30,000 shares of the company's stock valued at $160,000 after purchasing an additional 20,000 shares during the last quarter. Hedge funds and other institutional investors own 46.64% of the company's stock.</p>
<div class="lb-trans"><p>其他几家对冲基金和机构投资者最近也对 CRVS 的持仓进行了调整。Jane Street Group LLC 在第三季度收购了价值约 265,000 美元的 Corvus Pharmaceuticals 新头寸。Virtu Financial LLC 在第三季度购买了价值约 83,000 美元的 Corvus Pharmaceuticals 新股份。摩根大通在第三季度将其在 Corvus Pharmaceuticals 的持股增加了 441.5%。摩根大通现在拥有 49,556 股公司的股票，价值为 262,000 美元，此前在上个季度又收购了 40,404 股。Avity Investment Management Inc.在第四季度将其在 Corvus Pharmaceuticals 的持股增加了 7.6%。Avity Investment Management Inc.现在拥有 29,680 股公司的股票，价值为 159,000 美元，此前在上个季度又收购了 2,100 股。最后，Masso Torrence Wealth Management Inc.在第四季度将其在 Corvus Pharmaceuticals 的持仓提高了 200.0%。Masso Torrence Wealth Management Inc.现在拥有 30,000 股公司的股票，价值为 160,000 美元，此前在上个季度又购买了 20,000 股。对冲基金和其他机构投资者持有该公司 46.64% 的股份。</p>
</div><h2>Corvus Pharmaceuticals Trading Up 4.7 %</h2>
<div class="lb-trans"><h2>Corvus Pharmaceuticals 股价上涨 4.7%</h2>
</div><p>Shares of NASDAQ CRVS opened at $3.35 on Friday. The company has a 50 day simple moving average of $3.61 and a two-hundred day simple moving average of $5.51. The stock has a market cap of $228.37 million, a price-to-earnings ratio of -3.60 and a beta of 0.67. Corvus Pharmaceuticals, Inc. has a 12 month low of $1.75 and a 12 month high of $10.00.</p>
<div class="lb-trans"><p>NASDAQ CRVS 的股票在周五开盘价为 3.35 美元。该公司的 50 日简单移动平均为 3.61 美元，200 日简单移动平均为 5.51 美元。该股票的市值为 2.2837 亿美元，市盈率为-3.60，贝塔值为 0.67。Corvus Pharmaceuticals, Inc.的 12 个月低点为 1.75 美元，12 个月高点为 10.00 美元。</p>
</div><p>Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). Analysts forecast that Corvus Pharmaceuticals, Inc. will post -0.63 EPS for the current year.</p>
<div class="lb-trans"><p>Corvus Pharmaceuticals（NASDAQ:CRVS - 获取免费报告）最近在 5 月 5 日（星期一）发布了季度财报。该公司报告季度每股收益（EPS）为（0.13）美元，低于市场共识预期的（0.12）美元，差距为（0.01）美元。分析师预测 Corvus Pharmaceuticals, Inc.在本年度的每股收益将为-0.63 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>A number of brokerages have issued reports on CRVS. Oppenheimer restated an &#34;outperform&#34; rating and set a $15.00 price target (up previously from $14.00) on shares of Corvus Pharmaceuticals in a research note on Wednesday, March 26th. HC Wainwright reissued a &#34;buy&#34; rating and issued a $11.00 target price on shares of Corvus Pharmaceuticals in a research report on Wednesday, March 26th. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $15.67.</p>
<div class="lb-trans"><p>多家券商对 CRVS 发布了报告。Oppenheimer 在 3 月 26 日的研究报告中重申了 “跑赢大盘” 的评级，并将 Corvus Pharmaceuticals 的目标价设定为 15.00 美元（之前为 14.00 美元）。HC Wainwright 在 3 月 26 日的研究报告中重新发布了 “买入” 评级，并对 Corvus Pharmaceuticals 的目标价为 11.00 美元。一位投资分析师对该股票给予了卖出评级，三位分析师给予了买入评级，一位分析师给予了强烈买入评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 15.67 美元。</p>
</div><p><strong>Read Our Latest Report on Corvus Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Corvus Pharmaceuticals 的最新报告</strong></p>
</div><h2>Corvus Pharmaceuticals Profile</h2>
<div class="lb-trans"><h2>Corvus Pharmaceuticals 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.</p>
<div class="lb-trans"><p>Corvus Pharmaceuticals, Inc.是一家临床阶段的生物制药公司，专注于开发和商业化免疫调节剂产品候选药物，以治疗实体癌症、T 细胞淋巴瘤、自身免疫性疾病、过敏性疾病和传染病。其主要产品候选药物是 soquelitinib（CPI-818），这是一种选择性共价抑制剂，针对白细胞介素 2 诱导的 T 细胞激酶（ITK），目前正在进行多中心的 1/1b 期临床试验，治疗外周 T 细胞淋巴瘤、实体肿瘤和特应性皮炎。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Corvus Pharmaceuticals</li>
<li>TSX Venture Exchange (Formerly Canadian Venture Exchange)</li>
<li>IBM's AI Offensive: Assessing IBM's Path to Renewed Growth</li>
<li>Upcoming IPO Stock Lockup Period, Explained</li>
<li>Rockwell Automation: Tailwinds From Onshoring U.S. Production</li>
<li>Compound Interest and Why It Matters When Investing</li>
<li>Is Energy Transfer Undervalued or a Value Trap?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Corvus Pharmaceuticals</li>
<li>TSX 风险投资交易所（前称加拿大风险投资交易所）</li>
<li>IBM 的人工智能攻势：评估 IBM 重获增长的路径</li>
<li>即将到来的 IPO 股票锁定期，解读</li>
<li>罗克韦尔自动化：美国生产回流的顺风</li>
<li>复利及其在投资中的重要性</li>
<li>能源转移是被低估还是价值陷阱？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding CRVS?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 CRVS 吗？</strong> 访问 HoldingsChannel.com，获取 Corvus Pharmaceuticals, Inc.（NASDAQ:CRVS - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JWUw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=CRVS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Corvus Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Corvus Pharmaceuticals 吗？</h2>
</div><p>Before you consider Corvus Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Corvus Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corvus Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Corvus Pharmaceuticals 并不在名单上。</p>
</div><p>While Corvus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Corvus Pharmaceuticals 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

巴克莱银行（Barclays PLC）购买了 Corvus 制药公司（NASDAQ:CRVS）的股票